Oral antidiabetic therapy in patients with heart disease: A cardiologic standpoint

Herz

Volumn 29, Issue 3, 2004, Pages 290-298

  Fisman, Enrique Z ^c   Tenenbaum, Alexander ^c   Motro, Michael ^c   Adler, Yehuda ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c NONE

Author keywords

glucosidase inhibitors; Biguanides; Coronary artery disease; Diabetes; Glitazones Meglitinides; Sulfonylureas

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; DIGOXIN; FUROSEMIDE; GELATINASE B; GLIBENCLAMIDE; GLIMEPIRIDE; HOMOCYSTEINE; MEGLITINIDE; METFORMIN; MIGLITOL; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHENFORMIN; PIOGLITAZONE; POTASSIUM CHANNEL; QUINIDINE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; TRIAMTERENE; TROGLITAZONE; VOGLIBOSE;

ABDOMINAL PAIN; BLOOD CLOTTING DISORDER; CARDIOVASCULAR EFFECT; DIABETES MELLITUS; DIARRHEA; DRUG EXCRETION; DRUG METABOLISM; EDEMA; ENDOTHELIUM LESION; FLATULENCE; FOLIC ACID DEFICIENCY; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERHOMOCYSTEINEMIA; LACTIC ACIDOSIS; LIVER TOXICITY; MONOTHERAPY; REVIEW; THROMBOCYTE DYSFUNCTION; VITAMIN DEFICIENCY;

ADMINISTRATION, ORAL; ALPHA-GLUCOSIDASES; BENZAMIDES; BIGUANIDES; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; HEART; HEART DISEASES; HUMANS; HYPOGLYCEMIC AGENTS; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 2642586598     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-004-2476-5     Document Type: Review

References (58)

1. Wigard DL, Barrett-Connor E. Heart disease and diabetes. In: Harris MI, Cowie CC, Stern MP, et al., eds. Diabetes in America, 2nd edn. Washington/DC: US Government Printing Office, 1995:429-48.
2. Klimt CR, Knatterud GL, Meinert CL, et al. The University Group Diabetes Program; a study of the effect of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. I. Design, methods and baseline characteristics. II. Mortality results. Diabetes 1970;19:Suppl 2:747-830.
3. Smits P, Thien T. Cardiovascular effects of sulphonylurea derivatives. Implication for the treatment of NIDDM? Diabetologia 1995;38:116-21.
4. Brady PA, Terzic A. The sulfonylurea controversy: more questions from the heart. J Am Coll Cardiol 1998;31:950-6.
5. Innerfield RJ. Metformin-associated mortality in U.S. studies. N Engl J Med 1996;334:1611-3.
6. Misbin RI, Green L, Stadel BV, et al. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998;338:265-6.
7. Fisman EZ, Tenenbaum A, Benderly M, et al. Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up. Cardiology 1999;91:195-202.
8. Consensus Statement. The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care 1996;19:Suppl I:S54-61.
9. Nathan DM. Some answers, more controversy, from UKPDS. Lancet 1998;352:832-3.
10. Fertig BJ, Simmons DA, Martin DB. Therapy for diabetes. In: Harris MI, Cowie CC, Stern MP, et al., eds. Diabetes in America, 2nd edn. Washington/DC: US Government Printing Office, 1995:519-39.
11. DeFronzo RA. Pharmacologic therapy for type 2 diabetes. Ann Intern Med 1999;131:281-303.
12. Taylor SI, Accili D, Imai Y. Perspectives in diabetes: insulin resistance or insulin deficiency: which is the primary cause of NIDDM? Diabetes 1994;43:735-40.
13. University Group Diabetes Program. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VII. Evaluation of insulin therapy: final report. Diabetes 1982;31: Suppl 5:1-78.
14. Adler AI, Neil HAW, Manley SE, et al. Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom Prospective Diabetes Study (UKPDS 47). Am Heart J 1999;138:S353-9.
15. Adams JF, Clark JS, Ireland JT, et al. Malabsorption of vitamin B12 and intrinsic factor secretion during biguanide therapy. Diabetologia 1983;24:16-8.
16. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996;27:517-27.
17. Goldner MG, Knatterud GL, Prout TE. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. III. Clinical implication of UGDP results. JAMA 1971;218:1400-10.
18. Marchetti P, Navalesi R. Pharmacokinetic-pharmacodynamic relationships of oral hypoglycemic agents: an update. Clin Pharmacokinet 1989;16:100-28.
19. Rosenstock J, Samols E, Muchmore DB, et al. Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group. Diabetes Care 1996;19:1194-9.
20. + ATP channels in coronary vasodilation during exercise. Circulation 1993;88:1245-53.
21. + channels protect the myocardium against ischemia/reperfusion damage. Circ Res 1991;69:571-81.
22. Toombs CF, McGee DS, Johnston WE, et al. Myocardial protective effects of adenosine. Infarct size reduction with pretreatment and continued receptor stimulation during ischemia. Circulation 1992;86:986-94.
23. Pogatsa G, Koltai ZM, Ballagi-Pordany G. Influence of hypoglycemic sulfonylurea compounds on the incidence of ventricular ectopic beats in non-insulin-dependent diabetic patients treated with digitalis. Curr Ther Res 1993;53:329-39.
24. Grover GJ, Sleph PG, Dzwonick BS. Role of myocardial ATP-sensitive potassium channels in mediating preconditioning in the dog heart and their possible interactions with adenosine A1-receptors. Circulation 1992;86:1310-36.
25. Garratt KN, Brady PA, Hassinger NL, et al. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999;33:119-24.
26. Klepzig H, Kober G, Matter C, et al. Sulfonylureas and ischemic preconditioning. A double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 1999;20:439-46.
27. Fuhlendorff J, Rorsman P, Kofod H, et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998;47:345-51.
28. Hu S, Wang S, Dunning BE. Glucose-dependent and glucose-sensitizing insulinotropic effect of nateglinide: comparison to sulfonylureas and repaglinide. Int J Exp Diabetes Res 2001;2:63-72.
29. Fleming A. FDA approach to the regulation of drugs for diabetes. Am Heart J 1999;138:S339-45.
30. Lebovitz HE. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 2002;18:Suppl 2:S23-9.
31. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996;45:1661-9.
32. Duval C, Chinetti G, Trottein F, et al. The role of PPARs in atherosclerosis. Trends Mol Med 2002;8:422-30.
33. Bakris G, Viberti G, Weston WM, et al. Rosiglitazone reduces urinary albumin excretion in type 2 diabetes. J Hum Hypertens 2003;17:7-12.
34. Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679-84.
35. Goetze S, Bungenstock A, Czupalla C, et al. Leptin induces endothelial cell migration through Akt, which is inhibited by PPAR gamma-ligands. Hypertension 2002;40:748-54.
36. Nisoli E, Carruba MO, Tonello C, et al. Induction of fatty acid translocase/CD36, peroxisome proliferator-activated receptor-gamma2, leptin, uncoupling proteins 2 and 3, and tumor necrosis factor-alpha gene expression in human subcutaneous fat by lipid infusion. Diabetes 2000;49:319-24.
37. Chiasson JL, Josse RG, Gomis R, et al., STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-7.
38. Fisman EZ, Motro M, Tenenbaum A, et al. Impaired fasting glucose concentrations in nondiabetic patients with ischemic heart disease: a marker for a worse prognosis. Am Heart J 2001;141:485-90.
39. Tenenbaum A, Motro M, Fisman EZ, et al. Clinical impact of borderline and undiagnosed diabetes mellitus in patients with coronary artery disease. Am J Cardiol 2000;86:1363-6.
40. Rao SV, Bethel MA, Feinglos MN. Tratment of diabetes mellitus: implications of the use of oral agents. Am Heart J 1999;138:S334-7.
41. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005-12.
42. Fisman EZ, Tenenbaum A, Boyko V, et al. Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. Clin Cardiol 2001;24:151-8.
43. Olsson J, Lindberg G, Gottsater M, et al. Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia 2000;43:558-60.
44. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
45. Giugliano D. Does treatment of noninsulin-dependent diabetes mellitus reduce the risk of coronary heart disease? Curr Opin Lipidol 1996;7:227-33.
46. Tenenbaum A, Fisman EZ, Boyko V, et al. Prevalence and prognostic significance of unrecognized systemic hypertension in patients with diabetes mellitus and healed myocardial infarction and/or stable angina pectoris. Am J Cardiol 1999;84:294-8.
47. Tenenbaum A, Fisman EZ, Boyko V, et al. Hypertension in dietversus pharmacologically treated diabetics. Mortality over a 5-year follow-up. Hypertension 1999;33:1002-7.
48. Tenenbaum A, Motro M, Fisman EZ, et al. Status of glucose metabolism in patients with heart failure secondary to coronary artery disease. Am J Cardiol 2002;90:529-32.
49. The American Association of Clinical Endocrinologists. Medical guidelines for the management of diabetes mellitus: the AACE System of intensive diabetes self-management - 1999 update. Endocr Pract 2000;6:1-44.
50. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation 1999;100:1134-46.
51. Saku K, Zhang B, Shirai K, et al. Hyperinsulinemic hypoalphalipoproteinemia as a new indicator for coronary artery disease. J Am Coll Cardiol 1999;31:1443-51.
52. Fisman EZ, Tenenbaum A, Motro M. Antihyperglycemic treatment in type 2 diabetics with coronary artery disease: facts and questions. Heart Metab 2001;11:15-20.
53. Owens DR, Griffiths S. Insulin glargine (Lantus). Int J Clin Pract 2002;56:460-6.
54. Heinemann L, Pfutzner A, Heise T. Alternative routes of administration as an approach to improve insulin therapy: update on dermal, oral, nasal and pulmonary insulin delivery. Curr Pharm Des 2001;7:1327-51.
55. Heinemann L, Klappoth W, Rave K, et al. Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer. Diabetes Care 2000;23:1343-7.
56. Hashizume M, Douen T, Murakami M, et al. Improvement of large intestinal absorption of insulin by chemical modification with palmitic acid in rats. J Pharm Pharmacol 1992;44:555-9.
57. Mesiha MS, Plakogiannis F, Vejosoth S. Enhanced oral absorption of insulin from desolvated fatty acid-sodium glycocholate emulsion. Int J Pharm 1994;111:213-6.
58. Mesiha MS, Ponnapula P, Plakogiannis F. Oral absorption of insulin encapsulated in artificial chyles of bile salts, palmitic acid and alfa-tocopherol dispersions. Int J Pharm 2002;249:1-5.